patients with early gastric tumors and free of lymph node metastasis.
However, there are clinical limits for accurate tumor detection and diagnoses using preoperative examinations such as endoscopy, endoscopic ultrasonography (EUS), computed tomography (CT), and positron emission tomography-computed tomography. [2] [3] [4] Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are now commonly used as established serum markers in the clinical management of patients with gastric cancer. Nevertheless, the sensitivity and specificity of detecting patients with early gastric cancer are clinically insufficient and few candidate blood markers have clinical utility for overcoming these key problems. 5 Five-year survival rates of patients with International Union
Against Cancer stages IIIA, IIIB, and IV gastric cancers are 30.8-54.0%, 16.1-36.5%, and 9.2-23.9%, respectively. 6, 7 Furthermore, advances in chemotherapy have contributed to improvements in the prognosis of patients with advanced gastric cancer. 8 However, difficulties are associated with predicting tumor responses to chemotherapy and disease recurrence after surgery in patients with advanced stage cancer. Although blood monitoring using serum CEA and CA19-9 has been conventionally introduced for the managements of patients with gastric cancer, serum levels of conventional blood markers do not necessarily coincide with tumor behavior. 9 Therefore, surrogate blood markers are needed clinically to monitor tumor aggressiveness in real time. Moreover, liquid biopsy using blood specimens has the clinical benefit of being a simple and repeatable sampling tool.
In 1869, the presence of circulating tumor cells (CTC) in peripheral blood was proposed by Ashworth. 10 CTC are generally isolated from primary tumors or metastatic sites and these cells flow in the bloodstream of patients with malignancies. 11 To date, CTC have been focused on as a target for detecting occult tumors, predicting therapeutic responses and prognoses, and monitoring postoperative recurrence in the clinical management of patients with various malignancies, including gastric cancer. 12, 13 Non-invasive liquid biopsy has enabled CTC to be characterized and their numbers assessed. Therefore, the assessment of CTC using liquid biopsy may support new perspectives for the diagnosis and treatment of patients with gastric
cancer.
The present review will focus on the clinical significance of CTC as an important therapeutic target in gastric cancer, including recent topics. 16 Further studies are needed in order to resolve the problems associated with the detection of CTC using RT-PCR-based methods. management of patients with gastric cancer. In the near future, the advent of new blood markers is anticipated for the development of an RT-PCR-based approach to monitor CTC using liquid biopsy. Table 2 summarizes studies reported since 2007 on CTC assessed by cytometric-based methods using blood specimens from patients with gastric cancer. [47] [48] [49] [50] [51] [52] [53] [54] [55] The CellSearch system (Janssen Diagnostics, Raritan, NJ, USA) is one of the representative CTC detection assays using a cytometric-based method. This system has been approved by the American Food and Drug Administration (FDA) as a diagnostic tool for detecting CTC in patients with metastatic breast, colorectal, and prostate cancer. 56 In the CellSearch system, CTC are captured based on enrichment using antibody-coated magnetic beads with epithelial-cell adhesion molecules and discrimination using fluorescently labeled antibodies against CK and CD45.
| DETECTION OF CTC
We investigated the presence or absence of CTC in peripheral blood cells from patients with gastric cancer using the CellSearch system. 51 The findings obtained showed that CTC were morphologically detected using the CellSearch system, particularly in patients with unresectable advanced or recurrent gastric cancers. Recently, a new size-based separation system has been developed for enrichment and cultivation of CTC. 55 The greatest appeal of this system is that it can easily separate viable CTC from peripheral blood. Moreover, we can assess functional properties by culture of enriched viable CTC. Accordingly, the size-based filtration system may be focused as a novel tool for isolating viable CTC.
| INCIDENCE OF CTC
The incidence of CTC ranges between 11.6% and 98.6% in studies based on PCR-based methods (Table 1) . [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The gap observed in the incidence of CTC among each study may be as a result of differences in the clinicopathological backgrounds of enrolled patients, target markers, blood volumes assessed by PCR, and the cut-off values for mRNA levels. However, the incidence of CTC ranged between 36.6% and 52.2% in five RT-PCR studies targeting CEA, which is one of the conventional PCR markers for the detection of CTC. According to studies based on cytometric-based methods, the incidence of CTC ranges between 10.8% and 79.5% (Table 2) . [47] [48] [49] [50] [51] [52] [53] [54] [55] The CellSearch system was previously used to detect CTC in four (44.4%) out of nine studies using cytometric-based assays. 
| RELATIONSHIP BETWEEN CLINICOPATHOLOGICAL FACTORS AND CTC
To date, many investigators have reported a close relationship between positivity for CTC and well-known prognostic factors, such as tumor size, depth of tumor invasion, lymph node metastasis, stage, lymphatic and venous invasion. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [47] [48] [49] [50] [51] [52] [53] [54] [55] In a study on 94
patients with gastric cancer, we reported that the presence or absence of CTC evaluated by a qRT-PCR assay for the expression of B7-H4 correlated with the depth of tumor invasion, lymph node metastasis, stage, lymphatic invasion, and venous invasion (P = 0.006, P = 0.001, P < 0.001, P < 0.001, and P = 0.01, respectively). 28 In a study on 148 gastric cancer patients receiving surgical treatment, Uenosono et al. 51 reported that CTC assessed by the CellSearch system correlated with the depth of tumor invasion, lymph node metastasis, distant metastasis, stage, lymphatic invasion, and venous invasion (P = 0.009, P < 0.0001, P = 0.012, P = 0.0002, P = 0.0003, and P = 0.006, respectively). These findings suggest that blood assessments for the detection of CTC have the clinical power to predict tumor progression and malignant aggressiveness in patients with gastric cancer. CK, cytokeratin; CTC, circulating tumor cells; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; FACS, fluorescence-activated cell sorting; GFP, green fluorescent protein; HER, human epidermal growth factor receptor; ICC, immunocytochemistry; ISH, in situ hybridization; KRT, keratin; mo, months; MUC, mucin; OS, overall survival; UICC, International Union Against Cancer; -, undescribed.
| PROGNOSTIC IMPACT OF CTC
A large number of studies have investigated the clinical significance of CTC in patients with various malignancies, such as esophageal cancer, colorectal cancer, and pancreatic cancer. [57] [58] [59] Similarly, many investigators have assessed the prognostic impact of CTC in patients with gastric cancer, and most studies have suggested a close relationship between the presence of CTC and a poor prognosis. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [47] [48] [49] [50] [51] [52] [53] [54] [55] In a qRT-PCR study of 123 gastric cancer patients with stages I-IV, Qiu et al. 29 reported that 3-year disease-free survival (DFS) rates in patients who were positive or negative for CEA mRNA were 43.9% and 74.1%, respectively (P = 0.001). A multivariate analysis identified CEA mRNA positivity as an independent prognostic factor (P = 0.02). 29 Moreover, the sensitivity and specificity of CEA mRNA expression for predicting disease recurrence were 56.8% and 74.7%, respectively. 29 However, the sensitivity and specificity of the serum CEA status were 31.8% and 79.7%, respectively. 29 They concluded that the presence or absence of CTC by qRT-PCR detection for CEA mRNA was a promising predictor for disease recurrence in patients with gastric cancer. 29 In contrast, in a qRT-PCR study on 59 gastric cancer patients with stages I-IV, Ikeguchi and Kaibara reported that there were no significant differences in overall survival (OS) rates among patients with or without CEA mRNA expression (P = 0.744). 19 In that study, CTC were assessed using a qRT-PCR assay on blood specimens after gastrectomy. 19 The findings obtained indicated that CTC were destroyed shortly after gastrectomy. 19 They hypothesized host-related immunological defense mechanisms as one of the reasons for these findings. 19 Cao et al. 32 focused on survivin as a novel blood marker of CTC in a qRT-PCR study on 98 gastric cancer patients with stages I-IV. 32 They reported that 3-year DFS rates in patients who were positive or negative for survivin mRNA were 53.1% and 84.3%, respectively (P < 0.001). Furthermore, a multivariate analysis identified the status of survivin mRNA as an independent prognostic factor (P < 0.001).
32
In a study on 55 gastric cancer patients with stages I-IV, Yie et al.
showed that the specificity, sensitivity, and accuracy of survivinexpressing CTC for predicting disease recurrence were 100%, 100%, and 84.6%, respectively. 25 Bertazza et al. In recent years, immunotherapy has begun to attract attention as a drug treatment for patients with several malignant neoplasms. 60 According to the findings of a phase 1b trial on immunotherapy for patients with advanced gastric cancer, the anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab was found to be safe and exerted antitumor effects. 61 Although PD-1 is one of the representative molecules for immune checkpoints, we focused on other immune checkpoint molecules, such as B7-H3 and B7-H4. 28, 31 We investigated the prognostic impact of B7-H3 and B7-H4 in the peripheral blood of patients with stages I-IV gastric cancer. 28, 31 In a qRT-PCRbased study on 95 patients with gastric cancer, 5-year OS rates in patients who strongly or weakly expressed B7-H3 were 57.1% and 76.4%, respectively (P = 0.02). 31 Additionally, multivariate analyses selected the status of B7-H3 expression as an independent prognostic factor (P = 0.046). 31 In a B7-H4 study on 94 patients with gastric cancer, 5-year OS rates in patients who were positive or negative for mRNA expression were 60.4% and 87.2%, respectively (P = 0.04). 28 Our findings propose that the evaluation of B7-H3 and B7-H4 mRNA expression in blood specimens is useful as a CTC-associated tool for predicting the prognosis of patients with gastric cancer.
In a CellSearch study on 136 gastric cancer patients with stages I-IV, Okabe et al. 53 reported that progression-free survival was significantly shorter in patients with than in those without CTC (P = 0.016). All other studies based on the CellSearch system demonstrated that CTC had an influence on prognosis. 48 
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